MAR 25, 2019 10:36 AM PDT

Investigational Drug Reverses High Cholesterol and Non-Alcoholic Fatty Liver Disease

WRITTEN BY: Nouran Amin

A novel molecular pathway was recently discovered for an enzyme inhibitor in humans that is implicated in the development of high cholesterol and nonalcoholic fatty liver disease. Such conditions were found to be reversed in a mouse model using an investigational oral drug. The drug is known as TM5614 and is reported in a new research study to impede the actions of a multifunctional protein in the body known as plasminogen activator inhibitor 1, or PAI-1.

"High blood levels of PAI-1 are a hallmark of obesity, type 2 diabetes and metabolic syndrome, a cluster of risk factors for obesity-related diseases," said the study's lead researcher, Joshua Levine, M.D., Ph.D., an endocrinology fellow at Northwestern.

Learn more about non-alcoholic fatty liver disease:

The study was conducted based on findings that individuals who inherited a loss-of-function mutation in the gene that codes for PAI-1 have developed lower fasting insulin levels than those with unaffected relatives and appear protected from developing diabetes. Therefore, researchers were curious to see if blocking PAI-1 could reverse diet-induced obesity and its related health problems.

Specifically, the study investigated induced obesity in mice by feeding them a high-fat, high-sugar mice chow equivalent to fast food. Mice were then treated with the PAI-1 inhibitor TM5614. Results showed that after a week of treatment, the mice had improved fasting levels of blood sugar, insulin and LDL, or "bad" cholesterol, in compassion to untreated mice. Additionally, treated mice exhibited a "remarkable" reduction in fatty liver disease.

Learn more about LDL, “bad” cholesterol:

"This is important because PCSK9 inhibitors are the newest drug therapy available for the treatment of high cholesterol for people who do not benefit enough from statin cholesterol-lowering medicines or cannot tolerate statins," Levine said. "However, the high cost of these drugs limits their use, and they are injections, rather than pills. The drug may eventually become a less expensive and easier alternative to PCSK9 inhibitors."

Source: The Endocrine Society

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 19, 2020
Drug Discovery & Development
APR 19, 2020
FDA Approves New Drug for Breast Cancer
The US Food and Drug Administration has approved a new drug, known as tucatinib or Tuksya, as a treatment for advanced f ...
APR 24, 2020
Drug Discovery & Development
APR 24, 2020
Teenage Cannabis Use May Prime the Brain to Enjoy Cocaine
New research has found that teenage cannabis use may make the brain more susceptible to the effects of cocaine. "It ...
APR 27, 2020
Cancer
APR 27, 2020
The Tumor Suppressor and its Regulator: An Indirect Oncogene
Oncogenes, mutations in genes that promote cancer growth, have long been easy targets for cancer research due to the dir ...
APR 22, 2020
Drug Discovery & Development
APR 22, 2020
Using Colors To Track The Spread of Drug Particles
Forensic scientists from the National Institute of Standards and Technology (NIST) are relying on color to see the sprea ...
MAY 04, 2020
Immunology
MAY 04, 2020
GeoVax and Sino Bio Collaborate on COVID-19 Vaccine Work
GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and ...
MAY 21, 2020
Cancer
MAY 21, 2020
A New Player in the Regulation of Cancer's Microenvironment
Breast cancer is one of the most common cancers in the world.  Triple-negative breast cancer (TNBC) is a sub-type o ...
Loading Comments...